BMO-MRW best predictor of progression

Article

When detecting and evaluating the progression of glaucoma, Bruch's membrane opening-minimum rim width (BRO-MRW) may be the best predictor of the threshold of visual sensitivity and total deviation of visual field, according to a new study.

When detecting and evaluating the progression of glaucoma, Bruch's membrane opening-minimum rim width (BRO-MRW) may be the best predictor of the threshold of visual sensitivity and total deviation of visual field, according to a study published in Clinical Ophthalmology.

Japanese researchers examined the association between structural parameters of the optic nerve head and glaucomatous visual field indices in a total of 57 eyes in 33 patients with glaucomatous optic neuropathy.

The researchers measured the patients' visual fields, peripapillary retinal nerve fibre layer thickness (RNFL-T), BMO-MRW, and rim area. They then calculated Spearman's rank correlation coefficients between the threshold of visual sensitivity or total deviation of visual field and between the structural parameters as well as calculated RNFL-T and BMO-MRW volumes (each length multiplied by rim area).

They found that the threshold of visual sensitivity had the following correlation coefficients:

  • 0.23 with global sector of RNFL-T
  • 0.32 with BMO-MRW
  • 0.14 with rim area
  • 0.21 with RNFL-T volume
  • 0.26 with BMO-MRW volume

The correlation coefficients for each parameter with total deviation of visual field were as follows:

  • 0.22 with global sector of RNFL-T
  • 0.33 with BMO-MRW
  • 0.28 with rim area
  • 0.36 with RNFL-T volume
  • 0.37 with BMO-MRW volume

"Our study data confirm that total deviation was more strongly correlated with RNFL-T volume and BMO-MRW volume than with BMO-MRW. However, BMO-MRW appeared to be the best predictor of both the threshold of visual sensitivity and total deviation of visual field, and may be more useful for detecting and evaluating the progression of glaucoma," the researchers wrote.

To access the full article, click here.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.